@article {SkorupskaiteA160, author = {K Skorupskaite and L Stirrat and N Palaniappan and C Shearing and S Cowan}, title = {PPO.30 Assessment of adverse perinatal outcomes in women with isolated PAPP-A }, volume = {99}, number = {Suppl 1}, pages = {A160--A160}, year = {2014}, doi = {10.1136/archdischild-2014-306576.470}, publisher = {BMJ Publishing Group}, abstract = {Background Maternal serum pregnancy-associated-plasma-protein-A (PAPP-A) was introduced as a part of combined first trimester trisomy 21 screening (nuchal translucency, PAPP-A and human chorionic gonadotropin) in 2011. We aimed to investigate whether isolated low PAPP-A (\< 0.3MoM) was associated with stillbirth, preterm delivery and low birthweight in women booked for delivery in NHS Lothian in 2011. Methods We retrospectively reviewed case records of women with low PAPP-A level during 2011 (n = 154). Rate of stillbirth, preterm delivery and low birthweight were compared with a control group (n = 9603) who had a normal PAPP-A result, or had opted out of screening. Chi-squared test was used for comparison of rates. Statistical significance was considered at p \< 0.05. Results Rates of stillbirth, preterm delivery and low birthweight were significantly higher in women with low PAPP-A (Table 1). View this table:Abstract PPO.30 Table 1 Conclusions Our results suggest that low PAPP-A at first trimester screening is associated with significantly higher rates of stillbirth, preterm delivery and low birthweight.}, issn = {1359-2998}, URL = {https://fn.bmj.com/content/99/Suppl_1/A160.1}, eprint = {https://fn.bmj.com/content/99/Suppl_1/A160.1.full.pdf}, journal = {Archives of Disease in Childhood - Fetal and Neonatal Edition} }